Acute kidney injury in a patient on tenofovir alafenamide fumarate after initiation of treatment for hepatitis C virus infection

David P. Serota, Harold A. Franch, Emily J. Cartwright

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

HIV treatment with tenofovir alafenamide fumarate (TAF) has decreased renal toxicity compared with tenofovir disoproxil fumarate in clinical trials. We report the case of a patient with HIV/HCV coinfection who was started on a TAF-based HIV regimen and developed acute kidney injury that worsened with the addition of sofosbuvir-ledipasvir.

Original languageEnglish (US)
JournalOpen Forum Infectious Diseases
Volume5
Issue number8
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Keywords

  • Acute kidney injury
  • Hepatitis C
  • HIV infection
  • Tenofovir alafenamide

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Acute kidney injury in a patient on tenofovir alafenamide fumarate after initiation of treatment for hepatitis C virus infection'. Together they form a unique fingerprint.

Cite this